Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease

Clinica Chimica Acta

Volumn 411, Issue 3-4, 2010, Pages 267-269

  Inoue, Nao ^a   Takai, Shinji ^a   Jin, Denan ^a   Okumura, Kenichi ^a   Okamura, Naoyuki ^b   Kajiura, Mitsugu ^b   Yoshikawa, Sosuke ^b   Kawamura, Naohisa ^b   Tamai, Hiroshi ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Intravenous immunoglobulin; Kawasaki disease; Matrix metalloproteinase

Indexed keywords

C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; IMMUNOGLOBULIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY ANEURYSM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IC 50; IN VITRO STUDY; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 9; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEPTIDYL-DIPEPTIDASE A;

EID: 72449179991     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.11.020     Document Type: Article

References (25)

1. Suzuki A., Kamiya T., Kuwahara N., et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 7 (1986) 3-9
2. Newburger J.W., Takahashi M., Burns J.C., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315 (1986) 341-347
3. Burns J.C., Capparelli E.V., Brown J.A., Newburger J.W., and Glode M.P. Intravenous γ-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17 (1998) 1144-1148
4. Hashino K., Ishii M., Iemura M., Akagi T., and Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43 (2001) 211-217
5. Tremoulet A.H., Best B.M., Song S., et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 153 (2008) 117-221
6. Murphy G., Cockett M.I., Ward R.V., and Docherty A.J. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277 (1991) 277-279
7. Kelly D., Cockerill G., Ng L.L., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28 (2007) 711-718
8. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
9. Thompson R.W., Holmes D.R., Mertens R.A., et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96 (1995) 318-326
10. McMillan W.D., and Pearce W.H. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 29 (1999) 122-127
11. Pyo R., Lee J.K., Shipley J.M., et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105 (2000) 1641-1649
12. Takeshita S., Tokutomi T., Kawase H., et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 125 (2001) 340-344
13. Senzaki H., Masutani S., Kobayashi J., et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104 (2001) 860-863
14. Gavin P.J., Crawford S.E., Shulman S.T., Garcia F.L., and Rowley A.H. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 23 (2003) 576-581
15. Lau A.C., Rosenberg H., Duong T.T., McCrindle B.W., and Yeung R.S. Elastolytic matrix metalloproteinases and coronary outcome in children with Kawasaki disease. Pediatr Res 61 (2007) 710-715
16. Sorbi D., Fadly M., Hicks R., Alexander S., and Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 44 (1993) 1266-1272
17. Yamamoto D., Takai S., Jin D., Inagaki S., Tanaka K., and Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 43 (2007) 670-676
18. Japanese Circulation Society Joint Research Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. Pediatr Int 47 (2005) 711-732
19. Reinhardt D., Sigusch H.H., Hensse J., Tyagi S.C., Korfer R., and Figulla H.R. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
20. Lau A.C., Duong T.T., Ito S., and Yeung R.S. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum 58 (2008) 854-863
21. Lau A.C., Duong T.T., Ito S., Wilson G.J., and Yeung R.S. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 157 (2009) 300-309
22. Onoyama K., Hirakata H., Iseki K., et al. Blood concentration and urinary excretion of captopril (SQ 14, 225) in patients with chronic renal failure. Hypertension 3 (1981) 456-459
23. Richer C., Giroux B., Plouin P.F., Maarek B., and Giudicelli J.F. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol 17 (1984) 243-250
24. Sinaiko A.R., Mirkin B.L., Hendrick D.A., Green T.P., and O'Dea R.F. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr 103 (1983) 799-805
25. Momma K. ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs 8 (2006) 55-69